Check out our comprehensive educational activities here

What is the approach to the management of differentiation syndrome arising after therapy with IDH inhibitors?

In this activity, Dr. Fathi explains the manifestations of therapy with IDH inhibitors relative to the development of differentiation syndrome.

Published on November 3, 2021 in Treatment

What would be the best approach to the upfront therapy of IDH1/2 mutated AML among patients who are not eligible for intensive therapy?

Join Dr. Amir Fathi as he describes the best approach to upfront therapy for patients who are not eligible for traditional intensive therapy.

Published on October 28, 2021 in Treatment

Are patients who relapse after first-generation FLT3 inhibitors likely to respond to second-generation FLT3 inhibitors?

In this activity, Dr. Short describes FLT3 inhibitors after relapse and if they should be given alone or in combination.

Published on October 20, 2021 in Treatment

What are the prognostic implications of TP53 mutations in AML and what key clinical trials show promise for future treatment?

Join Dr. Short as he explains the prognostic implications of TP53 mutations in AML, including those with variant allele frequency.

Published on October 13, 2021 in Treatment

Why is it important to repeat genomic analysis at the time of AML relapse and what mutation should be tested?

In this activity, Dr. Nicholas Short discusses the approved drugs for various genomic abnormalities, including those in clinical trials.

Published on October 6, 2021 in Treatment

What is the efficacy of high-intensity therapy and stem cell transplant in older adults compared with younger patients?

Join Dr. Foran as he explains stem cell transplant in older and younger adults with AML.

Published on September 22, 2021 in Treatment

What are the current treatment options for older secondary acute myeloid leukemia (sAML) patients with myelodysplasia (MDS)-related changes?

Join Dr. Lancet as he discusses the treatment options for older secondary acute myeloid leukemia patients with myelodysplasia-related changes.

Published on September 15, 2021 in Treatment

What is the definition of secondary acute myeloid leukemia (sAML)?

It is important to differentiate between the two subtypes of sAML when deciding how to best treat these patients. In this activity, Dr. Kurtin describes treatments for both subtypes.

Published on September 8, 2021 in Treatment

What is the rationale for targeting BCL-2 in AML?

In this activity, Dr. Konopleva explains the rationale for targeting BCL-2 in AML.

Published on August 25, 2021 in Treatment

How do you determine patient fitness for intensive treatment?

Join Dr. Sweet as she discusses patient profiles and who should be considered fit or unfit for intensive therapy.

Published on August 18, 2021 in Treatment